Fermenta Biotech Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹133 Cr +1.9% YoYSee revenue, profit and what management said. You are viewing Q1 FY26.
FB

Fermenta Biotech Ltd

Q1 FY26Pharmaceuticals & Biotechnology

Fermenta Biotech Q1 FY26 earnings call: Revenue & Margins

Q1 FY26 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹136Cr
+74.4% YoY
−2.6% QoQ
Net profit
₹22Cr
Turned profitable YoY
−35.2% QoQ
Margin
20.73%
+19.7 pp YoY
−5.7 pp QoQ

Based on Fermenta Biotech Ltd's Q1 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹478
Market cap₹1.4K Cr
P/E25.5

The short version

Q1FY26 Revenue from operations: INR 136 crore, up 79% YoY (Page 8) - Total Income Q1FY26: INR 145 crore, up 79% YoY (Page 8) - Nutrition business revenue Q1FY26: INR 114.6 crore, up 85% YoY (Page 7) - Human Nutrition volume growth: 83% YoY, 8% QoQ (Page 5) - Animal Nutrition volume growth: 45% YoY, down 17% QoQ (Page 5) - German subsidiary Q1FY26 revenue: INR 15.7 crore, up 588% YoY (Page 5) - EBITDA Q1FY26 INR 37 crore, up 922% YoY (Page 6) - Profit after tax Q1FY26 INR 21.6 crore vs loss last year (Page 6) - EBITDA for Q1FY26: INR 37 crore (up 922% YoY, down 9% QoQ) — Slide 6 - Operating EBITDA (without Real Estate): INR 35.3 crore (up 625% YoY, up 9% QoQ) — Slide 5 - Profit After Tax (PAT) for Q1FY26: INR 21.6 crore (vs INR 5.9 crore loss YoY, down 35% QoQ) — Slide 6

From Fermenta Biotech Ltd's Q1 FY26 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q1FY26 Revenue from operations: INR 136 crore, up 79% YoY (Page 8)
  • Total Income Q1FY26: INR 145 crore, up 79% YoY (Page 8)
  • Nutrition business revenue Q1FY26: INR 114.6 crore, up 85% YoY (Page 7)
  • Human Nutrition volume growth: 83% YoY, 8% QoQ (Page 5)
  • Animal Nutrition volume growth: 45% YoY, down 17% QoQ (Page 5)
  • German subsidiary Q1FY26 revenue: INR 15.7 crore, up 588% YoY (Page 5)
  • EBITDA Q1FY26 INR 37 crore, up 922% YoY (Page 6)

2 more points from Fermenta Biotech Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Fermenta Biotech Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

There are references to: - Expansion in product portfolio and strategic acquisitions to rapidly expand capabilities (Page 14) — stated as strategic goals but without specifics.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Fermenta Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Fermenta Biotech Ltd said on order book & pipeline — free account, 30 seconds.

Fermenta Biotech Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Fermenta Biotech Ltd Q1 FY26 results — key figures

Fermenta Biotech Ltd Q1 FY26 reported results vs Q1 FY25, ₹ crore
₹ CrQ1 FY26Q1 FY25YoYQ4 FY25QoQ
Revenue13678+74.4%140-2.6%
Operating profit (EBITDA)281+3430%37-23.6%
Operating margin20.73%1.02%+19.7 pp26.42%-5.7 pp
Profit before tax28-6—32-12.2%
Net profit (PAT)22-6—33-35.2%
EPS (₹)7.42-1.98—11.68-36.5%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹133 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • RPG Life Sciences (Q1 FY26)

    168.9 crores vs Rs. Key concall takeaways from RPG Life Sciences Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

  • SMS Pharmaceuticals (Q1 FY26)

    Q1FY26 revenue from operations: ₹196.05 crore . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector…

  • Morepen Laboratories (Q1 FY26)

    Crores)**: . Key concall takeaways from Morepen Laboratories Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

  • NGL Fine Chem (Q1 FY26)

    Q1FY26 Revenue from operations: ₹104.19 crores . Key concall takeaways from NGL Fine Chem Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Fermenta Biotech Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Fermenta Biotech Ltd Q1 FY26 results?

Q1FY26 Revenue from operations: INR 136 crore, up 79% YoY (Page 8) - Total Income Q1FY26: INR 145 crore, up 79% YoY (Page 8) - Nutrition business revenue Q1FY26: INR 114.6 crore, up 85% YoY (Page 7) - Human Nutrition volume growth: 83% YoY, 8% QoQ (Page 5) - Animal Nutrition volume growth: 45% YoY, down 17% QoQ (Page 5) - German subsidiary Q1FY26 revenue: INR 15.7 crore, up 588% YoY (Page 5) - EBITDA Q1FY26 INR 37 crore, up 922% YoY (Page 6) - Profit after tax Q1FY26 INR 21.6 crore vs loss last year (Page 6) - EBITDA for Q1FY26: INR 37 crore (up 922% YoY, down 9% QoQ) — Slide 6 - Operating EBITDA (without Real Estate): INR 35.3 crore (up 625% YoY, up 9% QoQ) — Slide 5 - Profit After Tax (PAT) for Q1FY26: INR 21.6 crore (vs INR 5.9 crore loss YoY, down 35% QoQ) — Slide 6

What is Fermenta Biotech Ltd share price analysis?

Fermenta Biotech Ltd currently shows a neutral. The stock trades at a P/E of 25.5 with a market cap of ₹1,395 Cr. Investors should review the full earnings analysis for detailed insights.

Keep Fermenta Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.